Table 6.
Outcomes of Infections Due to Carbapenem-Resistant Enterobacteriaceae by Type of Infection and Overall
| Outcome | Number (%) of Patients | ||||
|---|---|---|---|---|---|
| Infection Type | |||||
| Bacteremia (N = 140) | HABP (N = 21) | VABP (N = 20) | cUTI/AP (N = 75) | All (N = 256) | |
| Duration of hospitalization for index CRE infectionb (mean ± SD) | 17.9 (17.5) | 11.7 (7.2) | 12.4 (6.4) | 8.2 (12.7) | 14.1 (15.4) |
| Duration of ICU stayb (mean ± SD) | 9.5 (15.8) | 7.7 (16.1) | 14.1 (12.0) | 3.6 (11.6) | 8.0 (14.7) |
| Number (%) With Clinical Cure (Study Investigator-Ascertained) | |||||
| Yes | 74 (52.9%) | 9 (42.9%) | 9 (45%) | 54 (72.0%) | 146 (57.0%) |
| No | 62 (44.3%) | 11 (52.4%) | 10 (50.0%) | 19 (25.3%) | 102 (39.8) |
| Unknown | 4 (2.9%) | 1 (4.8%) | 1 (5.0%) | 2 (2.7%) | 8 (3.1%) |
| CRE Organism Eradicated From Site of Infection, n (%) | |||||
| Yes | 78 (55.7%) | 8 (38.1%) | 10 (50.0%) | 38 (50.7%) | 134 (52.3%) |
| No | 51 (36.4%) | 10 (47.6%) | 9 (45.0%) | 29 (38.7%) | 99 (38.7%) |
| Unknown | 11 (7.9%) | 3 (14.3%) | 1 (5.0%) | 8 (10.7%) | 23 (9.0) |
| 28-Day Mortality, n (%) | |||||
| Yes | 45 (32.1%) | 7 (33.3%) | 7 (35.0%) | 13 (17.3%)a | 72 (28.1%) |
| No | 82 (58.6%) | 12 (57.1%) | 12 (60%) | 51 (68.0%) | 157 (61.3%) |
| Unknown | 13 (9.3%) | 2 (9.5%) | 1 (5.0%) | 11 (14.7%) | 27 (10.5%) |
Abbreviations: AP, acute pyelonephritis; CRE, carbapenem-resistant Enterobacteriaceae; cUTI, complicated urinary tract infection; HABP, hospital-acquired bacterial pneumonia; ICU, intensive care unit; PI, ; SD, standard deviation; VABP, ventilator-associated bacterial pneumonia.
aMortality rate among patients with cUTI/AP with concurrent bacteremia was 22.2%.
bDuration of hospitalization for index CRE infection refers to the duration of hospitalization required for treatment of the index CRE infection after diagnosis. Duration of ICU stay refers to the duration of ICU stay required for treatment of the index CRE infection.